Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Eton Pharmaceuticals (ETON) Change in Account Payables (2019 - 2025)

Historic Change in Account Payables for Eton Pharmaceuticals (ETON) over the last 7 years, with Q3 2025 value amounting to $2.1 million.

  • Eton Pharmaceuticals' Change in Account Payables rose 28442.03% to $2.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $11.6 million, marking a year-over-year increase of 112996.81%. This contributed to the annual value of $2.3 million for FY2024, which is 427358.49% up from last year.
  • Per Eton Pharmaceuticals' latest filing, its Change in Account Payables stood at $2.1 million for Q3 2025, which was up 28442.03% from $7.3 million recorded in Q2 2025.
  • Eton Pharmaceuticals' 5-year Change in Account Payables high stood at $7.3 million for Q2 2025, and its period low was -$1.3 million during Q4 2021.
  • In the last 5 years, Eton Pharmaceuticals' Change in Account Payables had a median value of $105000.0 in 2023 and averaged $625526.3.
  • In the last 5 years, Eton Pharmaceuticals' Change in Account Payables plummeted by 103308.82% in 2021 and then skyrocketed by 568846.15% in 2025.
  • Quarter analysis of 5 years shows Eton Pharmaceuticals' Change in Account Payables stood at -$1.3 million in 2021, then surged by 156.11% to $712000.0 in 2022, then crashed by 85.25% to $105000.0 in 2023, then soared by 1311.43% to $1.5 million in 2024, then soared by 43.18% to $2.1 million in 2025.
  • Its Change in Account Payables stands at $2.1 million for Q3 2025, versus $7.3 million for Q2 2025 and $705000.0 for Q1 2025.